Inotuzumab Ozogamicin as Single Agent in Pediatric Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia: Results from a Phase II Trial

Thirty-two patients were enrolled, 28 were treated, 27 were evaluable for response. The estimated overall response rate was 81.5%, and 81.8% of the responding subjects were minimal residual disease negative.